These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30569607)

  • 1. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma.
    Zhukova N; Rajagopal R; Lam A; Coleman L; Shipman P; Walwyn T; Williams M; Sullivan M; Campbell M; Bhatia K; Gottardo NG; Hansford JR
    Cancer Med; 2019 Jan; 8(1):40-50. PubMed ID: 30569607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
    Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
    Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
    Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
    Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
    Roux C; Revon-Rivière G; Gentet JC; Verschuur A; Scavarda D; Saultier P; Appay R; Padovani L; André N
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e630-e634. PubMed ID: 33235152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
    Gnekow AK; Kortmann RD; Pietsch T; Emser A
    Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
    Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
    Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
    J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
    J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
    Kalra M; Heath JA; Kellie SJ; Dalla Pozza L; Stevens MM; Swamy S; McCowage GB
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
    de Marcellus C; Tauziède-Espariat A; Cuinet A; Pasqualini C; Robert MP; Beccaria K; Puget S; Boddaert N; Figarella-Branger D; De Carli E; Bourdeaut F; Leblond P; Fouyssac F; Andre N; Bertozzi AI; Butel T; Dufour C; Valteau-Couanet D; Varlet P; Grill J
    J Neurooncol; 2022 Apr; 157(2):355-364. PubMed ID: 35239111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.
    Couec ML; André N; Thebaud E; Minckes O; Rialland X; Corradini N; Aerts I; Marec Bérard P; Bourdeaut F; Leblond P;
    Pediatr Blood Cancer; 2012 Jul; 59(1):34-8. PubMed ID: 22287258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis.
    Dong J; Meng X; Li S; Chen Q; Shi L; Jiang C; Cai J
    World Neurosurg; 2019 Oct; 130():e236-e243. PubMed ID: 31203059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
    Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
    J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
    Salloum R; DeWire M; Lane A; Goldman S; Hummel T; Chow L; Miles L; Sutton M; Stevenson C; Fouladi M; Leach J
    J Neurooncol; 2015 Feb; 121(3):591-8. PubMed ID: 25433556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.